|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 12/01/17 Organovo Holdings, Inc. 8-K:5 11/27/17 1:23K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 14K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 27, 2017 |
|
ORGANOVO HOLDINGS, INC. |
|
(Exact name of registrant as specified in its charter)
Commission File Number: 001-35996 |
|
Delaware |
|
27-1488943 |
|
(State or other jurisdiction of incorporation) |
|
(I.R.S. Employer Identification No.) |
|
6275 Nancy Ridge Dr., |
|
(Address of principal executive offices, including zip code) |
|
(858) 224-1000 |
|
(Registrant’s telephone number, including area code) |
|
|
|
|
|
(Former Name or Former Address, if Changed Since Last Report) |
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
|
|
|
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ |
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 30, 2017, Organovo Holdings, Inc. (the “Company”) announced the resignation of Dr. Eric David, one of its named executive officers, from his position as the Company’s Chief Strategy Officer and Executive Vice President of Preclinical Development, effective December 12, 2017. Dr. David is leaving the Company to join BridgeBio Pharma as a CEO-in-residence.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ORGANOVO HOLDINGS, INC. |
|
|
|
|
|
|
|
Date: November 30, 2017 |
/s/ Taylor Crouch |
|
|
|
|
|
Chief Executive Officer and President
|
|
|
|
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/12/17 | None on these Dates | |||
| Filed as of: | 12/1/17 | |||
| Filed on: | 11/30/17 | |||
| For Period End: | 11/27/17 | |||
| List all Filings | ||||